US-EN
Select Country
<br/>A broad range of imaging agents, procedures and devices that meet emerging medical challenges and facilitate clinical success <br/>One of the World's leading companies engaged in the development of new imaging solutions that address the evolving needs of patients <br/>Continuously invest in medical research and development, to provide innovative diagnostic products that match patients' needs <br/>A global partner with local resources. Everyday Bracco moves forward in all key diagnostic imaging modalities
1 2 3 4

Latest news

Bracco Diagnostics Inc. Creates First and Only U.S. FDA-Approved Multi-Dose Compliant Contrast Medium as Breakthrough Solution for Point-of-Care Use in the CT Suite

Bracco Diagnostic Inc. (BDI) today announced the availability of its innovative ISOVUE® (iopamidol injection) Imaging Bulk Package.

Press release

 

Bracco Diagnostics Inc. receives U.S. FDA Approval for new Ultrasound Contrast Agent

Lumason™ (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, now available for use in adults with suboptimal echocardiograms.

Press release

TRUTH Study

Click here to learn about the TRUTH1 Study.
Reference 1. Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Zižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study). AJNR Am J Neuroradiol. 2014 Oct 9. [Epub ahead of print]

Educational Events

AIMS

Established to compare various clinical approaches for targeted diagnostic imaging.

Read more

BAMRIS

Designed to help physicians stay abreast of the latest changes and applications in magnetic resonance.

Read more